LIVA-HEALTHCARE
13.5.2020 09:32:04 CEST | Business Wire | Press release
Liva Healthcare continues its UK growth plan with four new contracts as part of the Healthier You: NHS Diabetes Prevention Programme (NHS DPP). The NHS DPP is delivered by a group of providers including Liva and Living Well Taking Control (LWTC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005029/en/
This follows Liva's announcement of 13 contract wins across healthcare providers, insurance and pharmaceutical organisations at the start of 2020. The company also secured an investment of €8 million from three venture funds in 2019.
The four clinical commissioning groups (CCGs) that will now have access to Liva’s diabetes prevention programme are; Derbyshire, Nottinghamshire, Northamptonshire, and Worcester and Hereford. CCGs in Dorset, Shropshire, Wrekin, and Telford have already been welcomed onto the programme.
Over the next three years, as part of the Healthier You: NHS Diabetes Prevention Programme, Liva will deliver personal health coaching to almost 11,000 patients who are at high risk of Type 2 diabetes. This is in addition to nearly 44,000 patients who will have access to Liva's app to supplement a face-to-face intervention programme led by LWTC.
Liva Healthcare is a Copenhagen and London based health tech company that provides patients with access to a dedicated health coach for professional guidance, support, and empathy. Regular coaching sessions help patients tackle chronic conditions through sustainable lifestyle and behaviour changes. The Liva programme has been proven to halt and reverse the progression of Type 2 diabetes.
Kristoffer From, CEO at Liva Healthcare, says: " This is an exciting achievement and demonstrates our commitment to the UK healthcare industry. Taking on these contracts proves how adaptable and scalable our proposition is. We are proud to be a partner to the Healthier You: NHS Diabetes Prevention Programme.
"The NHS is leading the charge in the global fight against diabetes. This programme is the largest of its kind and by incorporating digital and face-to-face interventions, the NHS is demonstrating its commitment to healthcare innovation.
“It is important that patients at high risk of developing Type 2 diabetes can access support beyond traditional in-person services. Anybody going through our programme will receive professional guidance, support, and empathy, to help tackle or prevent chronic conditions through sustainable lifestyle and behavior changes."
Liva will continue to invest in its established markets across Europe, Asia-Pacific and Canada while it expands into key European growth markets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005029/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom